Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by RMR Wealth Builders

RMR Wealth Builders grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,490 shares of the biopharmaceutical company’s stock after acquiring an additional 2,117 shares during the quarter. RMR Wealth Builders’ holdings in Gilead Sciences were worth $1,400,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC increased its stake in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 216 shares during the last quarter. Morton Brown Family Wealth LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $35,000. Whipplewood Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $35,000. Synergy Investment Management LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $40,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $41,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 2.5%

Shares of NASDAQ GILD opened at $112.05 on Friday. The company has a market cap of $139.38 billion, a price-to-earnings ratio of 302.84, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 12-month low of $62.69 and a 12-month high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock’s 50 day simple moving average is $105.54 and its 200 day simple moving average is $102.06.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business’s revenue was down .3% on a year-over-year basis. During the same quarter last year, the business posted ($1.32) EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.82%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is 66.53%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Morgan Stanley increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Bank of America increased their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Finally, Oppenheimer lowered their target price on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the sale, the chief executive officer now owns 620,268 shares of the company’s stock, valued at $68,489,992.56. The trade was a 1.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total value of $266,000.00. Following the sale, the chief financial officer now directly owns 168,174 shares in the company, valued at $17,893,713.60. The trade was a 1.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,000 shares of company stock valued at $4,630,310 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.